Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI
ConditionNeurocognitive Dysfunction
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age5-39
SponsorTata Memorial Centre
About this trial
The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.
Eligibility criteria
Qualifiers
Age at irradiation: 5 to 39 years
Planned for CSI (with or without boost dose) with or without systemic chemotherapy
Informed consent or assent taken
Karnofsky Performance Status / Lansky Performance Status ≥ 60
Disqualifiers
Re-irradiation
Prior exposure to memantine
Inability to undergo Wechsler test
Trial design
Treatments tested in this trial
- Memantine Oral Tablet
Treatment groups
101 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov